<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> and <z:hpo ids='HP_0003202'>muscle wasting</z:hpo> are of critical importance to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients because of their negative effects on survival, functional status, and tolerability of chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Because previous data suggest vascular endothelial growth factor receptor inhibitors disrupt skeletal muscle pathways, such as PI3K and AKT, the current study explored <z:hpo ids='HP_0001824'>weight loss</z:hpo> and <z:hpo ids='HP_0003202'>muscle wasting</z:hpo> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients treated with bevacizumab </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were assessed for serial weight and radiographic changes in skeletal muscle at baseline and again within 3 months of starting <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Computed tomography scans were used to assess muscle </plain></SENT>
<SENT sid="4" pm="."><plain>Fifty-seven patients are the focus on this report </plain></SENT>
<SENT sid="5" pm="."><plain>These patients manifested a decline in mean weight from 85 to 83 kilograms (P = 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean skeletal muscle area at the L3 vertebral level dropped from 148 cm(2) to 145 cm(2) (P = 0.02) </plain></SENT>
<SENT sid="7" pm="."><plain>This drop in weight and skeletal muscle occurred independently of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>No statistically significant differences in survival were observed based on loss of weight or skeletal muscle </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> patients prescribed bevacizumab appear to lose weight and muscle over a few months even in the absence of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
</text></document>